Philip Morris Switzerland Sarl

Tridek-One is a biotech start-up developing first-in-class CD31 agonist modalities designed to restore the immune balance.

Beech Biotech is developing a novel treatment for preeclampsia, an severe unmet medical need that takes the lives of 70,000 women and 500,000 babies each year. The company is developing a novel placenta-impermeable antibody and works with a network of expert industry consultants and contractors.

XEMPERIA, a spin-off from the University of Fribourg, is pioneering a groundbreaking approach to blood testing that leverages the body's immune response to detect breast cancer at its earliest and most treatable stage.